Clinical Trial Update: Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS [Phase 1, Phase 2]

View source ↗

Summary

This document reports an ongoing Phase 1/Phase 2 clinical trial of ARD103 CAR-T therapy for relapsed/refractory acute myeloid leukemia and myelodysplastic syndr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• ARD103 CAR-T therapy (ARD103)

Snippet

Sponsor: ARCE Therapeutics, Inc. | Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1, Phase 2 | Status: RECRUITING